Astellas Pharma (OTCMKTS:ALPMY) Cut to “Hold” at Citigroup

Astellas Pharma (OTCMKTS:ALPMY) was downgraded by equities research analysts at Citigroup from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Astellas Pharma Stock Performance

OTCMKTS ALPMY opened at $14.03 on Monday. The company has a 50-day moving average of $13.25 and a 200-day moving average of $11.65. The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20. Astellas Pharma has a 12 month low of $8.37 and a 12 month high of $14.72.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.10. The company had revenue of $3.45 billion for the quarter, compared to analyst estimates of $3.14 billion. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.21%. On average, analysts anticipate that Astellas Pharma will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).